NEW YORK (GenomeWeb) – Indivumed has partnered with Singapore's Agency for Science, Technology, and Research (A*STAR) to perform proteomics research, with the aim of building out the company's IndivuType global cancer database.
According to Indivumed, IndivuType is an online resource that combines genomic, transcriptomic, proteomic, precision proteomic, and digital histopathology data with clinical information from thousands of cancer patients. It also features bioinformatic and artificial intelligence tools for data analysis.
Under the terms of the deal, Indivumed and A*STAR's Institute of Molecular and Cell Biology will perform proteomic and phosphoproteomic analyses on thousands of tissue samples from the company's cancer biobank. The resulting data will be added to IndivuType. Additional terms were not disclosed.
Earlier this year, Hamburg, Germany-based Indivumed secured a €40 million ($46.6 million) loan from the European Investment Bank that is being used, in part, to build IndivuType.